Action Medicenna Therapeutics - MDNA

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

1,04

Prix Achat

1,03

Prix Vente

1,05

Volume échangé

108 724

1,01 Fourchette du Jour 1,04

1,00 Plage de 52 semaines 2,98

Cap du marché

72,422M

Clôture Veille

1,01

Ouverture

1,01

Dernière Transaction

100

1.04

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

68 307

Actions en circulation

69 637 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,84

Bénéfice par action (BPA)

-0,37

Chiffre d'affairess

Bénéfice net

-25,47M

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.medicenna.com

Siège social

Toronto, Ontario, Can

Fondé

Medicenna Therapeutics Corp est coté dans le secteur Biological Pds,ex Diagnstics de la Toronto Stock Exchange avec le ticker MDNA. Le dernier cours de clôture d'Medicenna Therapeutics était de $1,01. Au cours de la dernière année, les actions de Medicenna Therapeutics ont été négociées dans une fourchette de prix de $ 1,00 à $ 2,98.

Medicenna Therapeutics compte actuellement 69 637 000 actions en circulation. La capitalisation boursière d'Medicenna Therapeutics est de $70,33 million. Medicenna Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.84.

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and...

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD...

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.15	-12.6050420168	1.19	1.19	1.01	58135	1.09516064	CS
4	-0.32	-23.5294117647	1.36	1.46	1.01	73439	1.24191864	CS
12	-0.97	-48.2587064677	2.01	2.07	1.01	68307	1.43049236	CS
26	-1.05	-50.2392344498	2.09	2.62	1.01	75096	1.78626218	CS
52	-0.3	-22.3880597015	1.34	2.98	1	99409	1.90755687	CS
156	-1.01	-49.2682926829	2.05	2.98	0.215	65051	1.40421293	CS
260	-2.21	-68	3.25	7.25	0.215	70327	2.68024296	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1,04

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69 637 000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 70,33M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 1,00 to $ 2,98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -2,84

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25,47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
LCFSTidewater Renewables Ltd	$ 1,72 (173,02%)	1,04M
TWMTidewater Midstream and Infrastructure Ltd	$ 0,20 (66,67%)	6,93M
GMTNGold Mountain Mining Corp	$ 0,025 (25,00%)	20k
FLNTFlint Corporation	$ 0,03 (20,00%)	47,02k
WLLWWillow Biosciences Inc	$ 0,04 (14,29%)	46k
BNGBengal Energy Ltd	$ 0,01 (-33,33%)	3k
VRTSVertiqal Studios Corporation	$ 0,02 (-20,00%)	2k
MSVMinco Silver Corp	$ 0,185 (-17,78%)	188,81k
DCBODocebo Inc	$ 46,42 (-13,80%)	385,69k
SLT.USaltire Capital Ltd	US$ 4,25 (-11,83%)	2,17k
MEGMEG Energy Corp	$ 22,54 (-1,79%)	19,52M
ENBEnbridge Inc	$ 61,81 (2,56%)	17,09M
CNQCanadian Natural Resources Ltd	$ 40,85 (0,12%)	16,17M
PKIParkland Corporation	$ 35,61 (-2,20%)	15,72M
VRNVeren Inc	$ 7,91 (4,49%)	9,79M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medicenna Therapeutics Corp (MDNA) Cours

Medicenna Therapeutics Corp (MDNA)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Medicenna Therapeutics Corp

MDNA Dernières nouvelles

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

MDNA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités